Phaseline

Companies › Norroy Bioscience

Norroy Bioscience: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
68Ga-NYM032
PSMA-targeting PET imaging agent
–Phase 3Prostate Cancer (Diagnosis); Prostate CancerJun 2027
177Lu-NYM032 injection
PSMA-targeting radioligand therapeutic agent
PSMAPhase 1Metastatic Castration-resistant Prostate Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06383052177Lu-NYM032 injectionPhase 1Metastatic Castration-resistant Prostate CancerOncologyJun 2025
NCT0761510168Ga-NYM032Phase 3Prostate Cancer (Diagnosis)OncologyJun 2027
NCT0764912268Ga-NYM032Phase 3Prostate CancerOncologyJun 2028

Targets

PSMA (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Inovio Pharmaceuticals Curium US Beijing Biotech

Companies built like this

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Clarity Pharmaceuticals C Ray Therapeutics Lantheus Medical Imaging Fusion Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.